CSI received COG approval by showing a cytogenetic abnormality price of 73 percent on submitted pediatric acute lymphoblastic leukemia situations. This far exceeded the mandatory rate of 55 percent. In addition to cancer cytogenetic examining, the genetics group at CSI Laboratories presents a complete menu of fluorescence in-situ hybridization assays for the analysis and monitoring of hematopoietic and solid-tumor diseases.. Heart and Mind targets for better dementia avoidance Although absolute prevention of dementia isn’t possible, better dementia avoidance is achievable and very important certainly. A new focus on promoting a dynamic cognitive life-style along with cardiovascular risk element reduction is recommended.‘The info being presented at this year’s ESMO Congress, including new denosumab and AMG 386 analyses, reflect the breadth and diversity of Amgen’s oncology portfolio.’ Abstracts will be available on the ESMO website at following the meeting.. Amgen to discuss data helping Repatha BLA for high cholesterol treatment with FDA EMDAC Amgen today announced that the business will discuss the info helping the RepathaTM Biologics License Software for the treating high cholesterol with the U.S. Food and Drug Administration's Endocrinologic and Metabolic Medicines Advisory Committee . Repatha is an investigational fully individual monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 , a protein that decreases the liver's capability to remove low-density lipoprotein cholesterol , or ‘poor’ cholesterol, from the bloodstream.